

Activation of the latent PlcR regulon in *Bacillus anthracis*

Inka Sastalla,¹ Lauren M. Maltese,¹ Olga M. Pomerantseva,^{2†}
Andrei P. Pomerantsev,¹ Andrea Keane-Myers² and Stephen H. Leppla¹

Correspondence
Stephen H. Leppla
sleppla@niaid.nih.gov

¹Laboratory of Bacterial Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

²Biological Defense Research Directorate, Naval Medical Research Center, Rockville, MD, USA

Many genes in *Bacillus cereus* and *Bacillus thuringiensis* are under the control of the transcriptional regulator PlcR and its regulatory peptide, PapR. In *Bacillus anthracis*, the causative agent of anthrax, PlcR is inactivated by truncation, and consequently genes having PlcR binding sites are expressed at very low levels when compared with *B. cereus*. We found that activation of the PlcR regulon in *B. anthracis* by expression of a PlcR–PapR fusion protein does not alter sporulation in strains containing the virulence plasmid pXO1 and thereby the global regulator AtxA. Using comparative 2D gel electrophoresis, we showed that activation of the PlcR regulon in *B. anthracis* leads to upregulation of many proteins found in the secretome of *B. cereus*, including phospholipases and proteases, such as the putative protease BA1995. Transcriptional analysis demonstrated expression of BA1995 to be dependent on PlcR–PapR, even though the putative PlcR recognition site of the BA1995 gene does not exactly match the PlcR consensus sequence, explaining why this protein had escaped recognition as belonging to the PlcR regulon. Additionally, while transcription of major PlcR-dependent haemolysins, sphingomyelinase and anthrolysin O is enhanced in response to PlcR activation in *B. anthracis*, only anthrolysin O contributes significantly to lysis of human erythrocytes. In contrast, the toxicity of bacterial culture supernatants from a PlcR-positive strain towards murine macrophages occurred independently of anthrolysin O expression *in vitro* and *in vivo*.

Received 10 May 2010
Revised 28 July 2010
Accepted 29 July 2010

INTRODUCTION

Bacillus cereus and *Bacillus anthracis*, members of the *B. cereus* group of bacteria, have high genetic similarity (Ivanova *et al.*, 2003; Read *et al.*, 2003), and may even constitute a single species (Helgason *et al.*, 2000). While *B. cereus* is an opportunistic human pathogen (Drobniewski, 1993), *B. anthracis* is the aetiological agent of anthrax, a disease with a high lethality in many animal species, including humans (Mock & Fouet, 2001). The strikingly different behaviour of these closely related species is attributed to *B. anthracis* having several additional genetic features, such as the virulence plasmids pXO1 and pXO2. These plasmids encode genes for the anthrax tripartite toxin, composed of protective antigen (PA), lethal factor (LF) and oedema factor (EF), and genes for the biosynthetic enzymes for the antiphagocytic poly- γ -D-glutamic acid capsule (Mock & Fouet, 2001). Another unique genetic trait involves the pleiotropic transcriptional regulator PlcR

(Agaisse *et al.*, 1999; Lereclus *et al.*, 1996). In *B. cereus*, PlcR acts by binding to a well-defined site (the PlcR box), consisting of a 16 bp consensus sequence present in promoter regions of PlcR-regulated genes (Agaisse *et al.*, 1999; Okstad *et al.*, 1999). Furthermore, PlcR action requires the participation of a secreted, processed and reimported heptapeptide derived from PapR (Bouillaut *et al.*, 2008; Lereclus *et al.*, 1996; Okstad *et al.*, 1999; Slamti *et al.*, 2004). Comparative protein and RNA expression profiles of PlcR-positive and -negative *B. cereus* and *Bacillus thuringiensis* strains have identified genes regulated by PlcR that encode collagenases, haemolysins, phospholipases and enterotoxins (Gohar *et al.*, 2002, 2008; Slamti *et al.*, 2004). Conversely, in *B. anthracis*, a nonsense mutation in *plcR* results in a premature translational stop (Agaisse *et al.*, 1999; Slamti *et al.*, 2004), and consequently gene expression in *B. anthracis* differs drastically from that in *B. cereus*. Certain phenotypic properties of *B. anthracis*, such as lack of haemolytic activity towards erythrocytes (Burdon, 1956), can be attributed to the non-functional PlcR, even though the genes for at least two haemolysins are present in the *B. anthracis* genome. The best-characterized haemolysin of *B. anthracis* is anthrolysin O, a member of the

†Deceased.

Abbreviations: BMDMs, bone marrow-derived macrophages; LF, lethal factor; LT, lethal toxin; PA, protective antigen.

cholesterol-dependent family of haemolysins, which causes lysis of a variety of cells (Mosser & Rest, 2006; Shannon *et al.*, 2003; Tweten, 2005). Although *B. anthracis* strains are non-haemolytic on blood agar plates, this PlcR-dependent haemolysin is expressed under certain culture conditions as well as *in vivo* (Ross & Koehler, 2006; Shannon *et al.*, 2003).

In *B. anthracis*, studies of the putative PlcR regulon have been restricted to sequence searches for PlcR boxes and comparisons with *B. cereus*, and have resulted in the identification of about 50 *B. anthracis* genes that are potentially subject to regulation by PlcR (Mignot *et al.*, 2001; Rasko *et al.*, 2005; Read *et al.*, 2003). Several studies report the activation of the PlcR regulon in *B. anthracis* (Mignot *et al.*, 2001; Pomerantsev *et al.*, 2003, 2004). One study shows that expression of PlcR in *B. anthracis* affects sporulation of bacteria containing the virulence plasmid pXO1, but not of bacteria lacking either pXO1 or the pXO1-encoded regulator AtxA alone, and it has been hypothesized that in *B. anthracis*, functional PlcR is incompatible with AtxA-controlled gene regulation (Mignot *et al.*, 2001). However, subsequent reports have described haemolytic *B. cereus* strains having pXO1-like plasmids (Hoffmaster *et al.*, 2004, 2006; Klee *et al.*, 2006), and a recent report describes the presence of two AtxA homologues in a *B. cereus* strain containing an active PlcR regulator (Passalacqua *et al.*, 2009). These observations motivated us to readdress the hypothesis that AtxA cannot coexist with an active PlcR system. We have previously shown that the haemolytic activity of *B. anthracis* can be drastically increased upon introduction of plasmid pFP12 containing a PlcR–PapR fusion protein, leading to growth phase-independent activation of the PlcR regulon in *B. anthracis*. This fusion protein contains a full-length PlcR fused to PapR after deletion of the stop codon and one of three repetitive MKK motifs (Pomerantsev *et al.*, 2004). In this study, using plasmid pFP12, we investigated the effect of a functional PlcR regulon in *B. anthracis* with regard to sporulation, protein expression, anthrolysin-dependent haemolysis, and toxicity towards macrophages *in vitro* and *in vivo*.

METHODS

Bacterial strains, media and growth conditions. Table 1 lists all strains and plasmids used in this study. Bacteria were routinely grown in Luria–Bertani (LB), Brain–Heart Infusion (BHI; BD Biosciences) or nutrient broth with yeast extract (NBY) containing 0.8% nutrient broth (Sigma), 0.3% yeast extract, 9% heat-inactivated equine serum (Hyclone), and 0.6% NaHCO₃ at 37 °C and 225 r.p.m. in either air or air supplemented with CO₂ regulated at 5% for media supplemented with NaHCO₃. AtxA functionality was tested for bacteria grown in NBY broth. Spores were prepared as described previously (Sastalla *et al.*, 2009). For haemolytic studies, bacteria were grown on tryptic soy agar with 5% sheep blood (both BD Biosciences) or BHI broth. When required, the following antibiotics were added to *Escherichia coli* or *B. anthracis* cultures: ampicillin (100 µg ml⁻¹), erythromycin (10 µg ml⁻¹), kanamycin (20 µg ml⁻¹), tetracycline (10 µg ml⁻¹) and spectinomycin (150 µg ml⁻¹). All antibiotics were purchased from Sigma.

DNA techniques and mutagenesis. For generating an anthrolysin knockout strain, two *alo*-adjacent fragments were amplified using primers ALL and ALR (fragment *alo*LF), and primer ARL in combination with ARR (fragment *alo*RF), harbouring *Eco*RI and *Spe*I sites, respectively (Table 1). Amplified fragments were separately cloned into vector pSC, a plasmid allowing sequential generation of markerless deletions using the Cre/Lox system (Pomerantsev *et al.*, 2009). Briefly, plasmid pSC-*alo*LF was introduced into *B. anthracis*; electrocompetent cells were prepared as described previously (Park & Leppla, 2000). Transformants were selected at 30 °C on erythromycin and chromosomal integration of the plasmid was achieved by a temperature shift to 37 °C. Plasmid pCrePAS was introduced, resulting in excision of the inserted plasmid backbone by Cre-recombinase activity, leaving a single loxP site. Plasmid pSC-*alo*RF was introduced and the 30 °C/37 °C selection cycle followed by introduction of pCrePAS was repeated, resulting in excision of residual vector and the entire *alo* gene from the bacterial chromosome.

Plasmid pFP12 (Pomerantsev *et al.*, 2004) was introduced by electroporation. To verify the presence (i.e. retention) of pXO1 in *B. anthracis*, bacteria were resuspended in Tris/EDTA buffer (Quality Biological), boiled for 2 min, and supernatants were used as template for the PCR using *Taq* polymerase (Qiagen) and PA (*pagA*) gene primers PA1 and PA2 (Table 1). For sequencing of *atxA*, primers AtxSeq1 and AtxSeq5 generated a 1742 bp PCR product that was subsequently used as template for sequencing reactions using primers AtxSeq1, AtxSeq2, AtxSeq3, AtxSeq4 and AtxSeq5.

Sporulation efficacy. Bacteria were grown on sporulation agar (Sastalla *et al.*, 2009) for 5 days, analysed microscopically using a Nikon Eclipse TE200U microscope, scraped off the plates, and resuspended in 1 ml sterile distilled water. Spore suspensions were heat-treated at 65 °C for 30 min and plated on LB agar. The percentage of viable spores was calculated using the following equation:

$$(\text{c.f.u. after heat treatment} / \text{c.f.u. before heat treatment}) \times 100$$

2D SDS-PAGE and protein identification. Bacteria were grown to the late exponential/early stationary growth phase and centrifuged at 9000 g, and filter-sterilized supernatants were precipitated with TCA (10% final concentration), washed in ice-cold acetone and resuspended in 2D-rehydration buffer [8 M urea, 2% (w/v) CHAPS, 0.5% (v/v) ZOOM carrier ampholytes for pH range 3–10 (Invitrogen), 0.002% bromophenol blue, 20 mM DTT]. Proteins were quantified using 2D Quant (Amersham), and 50 µg was separated on a NuPAGE gel using the IPG Runner system (Invitrogen) according to the manufacturer's recommendations. Gels were Coomassie-stained and spots of interest were excised, trypsin-digested and analysed by MS. Retrieved data were searched against the *B. anthracis* Ames strain database using Mascot as the search engine. Peptides with a Mascot protein score higher than 60 were considered significant, and the most abundant protein present in each spot is listed in Table 2. MS-MS analysis was performed at the National Institute of Allergy and Infectious Diseases (NIAID) Research Technology Branch (RTB) Core Facility. Protein alignments and sequence analyses were performed using Lasergene MEGALIGN, PSORTb (Gardy *et al.*, 2005), SignalP (Emanuelsson *et al.*, 2007), Prosite (<http://expasy.org/prosite>) and TMpred (<http://www.ch.embnet.org>).

Western blotting. Filter-sterilized supernatants of bacterial cultures grown in NBY medium to stationary phase were separated on NuPAGE gels (Invitrogen) and blotted onto nylon membranes (Osmonics). Membranes were incubated with 2 µg mouse monoclonal antibodies ml⁻¹ against either PA (PA-05-A-G1) or LF (LF-03-A-G1) (both from the Naval Medical Research Center) in 1% skim milk, and anti-mouse IgG conjugated to horseradish peroxidase (KPL) was used as secondary antibody. Membranes were developed using a tetramethylbenzidine (TMB) peroxidase substrate (KPL).

Table 1. *Bacillus* strains, plasmids and primers used in this study

Restriction sites are underlined.

Strain, plasmid or primer	Relevant characteristic(s)	Source or reference
<i>B. anthracis</i> strains		
Sterne 34F2	pXO1 ⁺ , PlcR ⁻	Ivins <i>et al.</i> (1986)
SdT	34F2, pXO1 ⁻ , PlcR ⁻	
SdT12	34F2, pXO1 ⁻ , harbouring pFP12, PlcR ⁺	Pomerantsev <i>et al.</i> (2004)
Sterne pFP12	34F2 harbouring pFP12, PlcR ⁺ (pXO1 ⁺)	This study
Sterne ΔALO	34F2, anthrolysin-negative (pXO1 ⁺)	This study
Sterne ΔALO pFP12	34F2, anthrolysin-negative, harbouring pFP12, PlcR ⁺ (pXO1 ⁺)	This study
<i>B. cereus</i> strain		
569		Reddy <i>et al.</i> (1987)
<i>E. coli</i> strains		
TOP10		Invitrogen
XL2-Blue		Stratagene
SCS110		Stratagene
Plasmids		
pFP12	Encodes a PlcR–PapR fusion protein	Pomerantsev <i>et al.</i> (2004)
pSC	Contains <i>loxP</i> site for <i>B. anthracis</i> mutagenesis	Pomerantsev <i>et al.</i> (2009)
pSC-aloLF	pSC with ALL and ALR-derived amplicon	This study
pSC-aloRF	pSC with ARL and ARR-derived amplicon	This study
pCrePAS	Contains Cre recombinase	Pomerantsev <i>et al.</i> (2009)
Primers		
	Sequence (5'–3')	Relevant property
ALL	ccccgaattcagaagcagaaagcccgcat	Amplification of aloLF
ALR	cccactagtcggctgtgttctgcaaaa	
ARL	ccccgaattcttgcatgggaatgggtgaga	Amplification of aloRF
ARR	cccactagttgcccccaatagactcaa	
PA1	gattcaggcagaagttaaacagg	Amplification of <i>pagA</i>
PA2	cccaccaatatcaagaacg	
AtxSeq1	tgctatttcaatagaagaacaaaa	Used to sequence AtxA
AtxSeq2	tccaagatggaggaatttcg	
AtxSeq3	tgcaatccttagctcaaaactc	
AtxSeq4	ccttggctaagaattacc	
AtxSeq5	tatccatcgctatgcaggtg	
BA1995fw	cgcgtcatctgtatcttatgc	
BA1995rv	agcttgccatttctgtgc	Used for BA1995 RT-PCR
Sph1	tatccgaattggggacaaaag	Used for <i>sph</i> RT-PCR
Sph2	gaagcgtgcaatgttttgaa	
Alo1	tgtggctggagcagtagatg	Used for <i>alo</i> RT-PCR
Alo2	cactcgtttcgacgctgta	
GyrAfw	aaaacctgtgcatcgtagg	Used for <i>gyrA</i> RT-PCR
GyrArv	acattagcattggcatcacg	

RNA isolation and RT-PCR. Cultures grown in BHI to late exponential/stationary phase were centrifuged, and RNA was stabilized using RNA Protect Bacteria reagent (Qiagen) before further isolation using a Qiagen RNeasy kit. Further preparation of RNA and RT-PCR was performed as described previously (Sastalla *et al.*, 2009). To amplify targeted mRNAs, the following oligonucleotides were used: primers BA1995fw in combination with BA1995rv, primers Sph1 and Sph2, and primers Alo1 and Alo2 (Table 1). Internal control reactions were performed with primers GyrAfw and GyrArv as described previously (Sastalla *et al.*, 2009). Band intensities were quantified using ImageJ version 1.40 g.

Haemolytic assays. Human blood obtained from the National Institutes of Health (NIH) Blood Bank was washed with PBS and

resuspended in PBS to the original volume. A 40 µl volume of blood was mixed with 160 µl culture supernatant obtained from bacteria grown in BHI medium to which 20 mM cysteine had been added, incubated at 37 °C for 45 min and centrifuged at 500 g, and the A_{540} of supernatants was measured in a SpectraMAX 190 plate reader (Molecular Devices). A haemolysis value of 100% corresponded to haemolysis obtained by addition of 0.1% SDS in BHI broth. For some experiments, cholesterol at a final concentration of 25 µM was added.

Preparation and use of bone marrow-derived macrophages (BMDMs). Bone marrow cells from 8–14-week old DBA/2J mice (Jackson Laboratories) were cultured in two parts complete Dulbecco's modified Eagle's medium (DMEM) [10% fetal bovine serum (FBS), 10 mM HEPES, 50 µg gentamicin ml⁻¹] and one part L929 cell culture

Table 2. Proteins identified by 2D gel electrophoresis

Gene ID	Description	Loc.*	<i>M_r</i>	pI
<i>B. anthracis</i>				
BA0885	S-layer protein SAP	CW	86.6	7.6
BA0887	S-layer protein EA1	CW	91.4	5.8
BA0796	Conserved hypothetical protein	E	40.8	9.6
BA1449	Peptidase, M23/M37 family	E	46.2	6.7
BA1952	NLP/P60 family protein	CW	43.9	10.2
<i>B. anthracis</i> pFP12				
BA0267	GroEL, 60 kDa chaperonin†	C	57.4	4.5
BA0555	Putative collagenase†	E	109.9	5.0
BA0620	Putative 8-amino-7-oxononanoate synthase	C	43.1	5.7
BA0670	Putative transaldolase	C	23.1	5.3
BA0672	InhA metalloprotease†	E	87.9	5.7
BA0677	Phospholipase C†‡	E	32.4	7.9
BA1887	Enterotoxin†‡	E	43.6	4.8
BA1995	Putative protease†‡	E	43.9	9.0
BA2032	Hypothetical protein‡	E	16.2	8.9
BA3162	Putative 5'-nucleotidase†	C	57.8	6.5
BA3891	Phosphatidylinositol diacylglycerol-lyase†‡	E	38.1	7.9
BA3962	Ribosome recycling factor	C	20.7	5.5
BA3964	Translation elongation factor Ts	C	32.4	5.0
BA4181	Pyruvate dehydrogenase complex E3 component, dihydrolipoamide dehydrogenase†	C	49.5	5.0
BA4184	Pyruvate dehydrogenase complex E1 component, alpha subunit	C	41.4	5.6
BA4194	Putative 2,3,4,5-tetrahydropyridine-2-carboxylate <i>N</i> -succinyltransferase	C	25.7	5.2
BA4499	Superoxide dismutase, Mn†	E	22.7	5.3
BA5130	Phosphoglucose isomerase	C	50.3	4.8
BA5364	Enolase†	C	46.4	4.4
BA5470	Sulfatase	MA	73.5	6.4
BA5580	Fructose-bisphosphate aldolase, class II	C	30.7	4.8

*Cellular location: C, cytoplasmic/unknown; CW, cell wall; MA, membrane-associated; E, extracellular.

†Protein found in supernatants of *B. cereus*.

‡PlcR box present.

supernatant for 7 days. Cells were washed and resuspended in serum-free DMEM, and 80 µl aliquots were transferred to 96-well microtitre plates. Filter-sterilized bacterial culture supernatants (25 µl) harvested from BHI-grown bacteria were added, and plates were incubated for 4 h at 37 °C and 5% CO₂. For some experiments, supernatants were heat-treated at 95 °C for 10 min before addition to cells. To determine the viability of cells, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) was added at a final concentration of 1 mg ml⁻¹, and pictures of the stained (viable) cells were taken after incubation for 45 min at 37 °C in 5% CO₂. The amount of formazan produced by viable cells was quantified at 590 nm after removal of medium and addition of 50 µl dissolving buffer containing 0.5% SDS and 25 mM HCl dissolved in 90% 2-propanol.

Intraperitoneal treatment of mice and isolation of cells. DBA/2J mice (8–14 weeks old, *n*=2 in at least three independent studies) received intraperitoneal injections of 500 µl filter-sterilized bacterial culture supernatants or BHI alone. After an incubation period of 45 min, intraperitoneal lavages were performed with PBS containing 1% BSA (PBSA). For some experiments, digital images of lavage samples were taken, or samples were centrifuged, treated twice with ammonium chloride lysing buffer (ACK; Invitrogen) to eliminate red

blood cells, washed two more times with PBSA, and resuspended in 600 µl of the same buffer. Animal experiments described in this and the previous section were performed according to NIH and Animal Welfare Act guidelines and approved by the Animal Care and Use Committee of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

Flow cytometry analyses. Cell suspensions in PBSA were incubated with rat anti-mouse CD32 antibodies (BD Biosciences) for blocking of the Fc receptor, followed by allophycocyanin (APC)-conjugated anti-mouse F4/80 (AbD Serotec) to label macrophages. After incubation for 30 min at 4 °C, cells were washed with PBSA and subjected to flow cytometric analysis using an LSR II flow cytometer (BD Biosciences). Data were analysed either in DIVA software (BD Biosciences) or in FlowJo version 7 (Tree Star).

Statistics. A *t* test or one-way ANOVA was performed for unpaired data (sporulation efficacy and macrophage retrieval from mice), and a paired *t* test was performed for paired data (cholesterol inhibition and *in vitro* treatment of macrophages with heat-inactivated/non-heated supernatant) in GraphPad Prism version 5.01.

RESULTS

AtxA regulation does not interfere with sporulation in *B. anthracis* expressing PlcR–PapR

We readdressed the hypothesis that expression of functional PlcR is incompatible with pXO1-encoded, AtxA-controlled gene regulation. Expression of the PlcR–PapR fusion protein encoded by plasmid pFP12 (Pomerantsev *et al.*, 2004) in *B. anthracis* strain Sterne 34F2 resulted in colonies that were highly haemolytic on blood agar plates (Fig. 1a). Microscopic analyses of the parental and PlcR–PapR-positive (Sterne pFP12) strains surprisingly showed that both strains readily formed spores (Fig. 1b).




Fig. 1. Characterization of PlcR–PapR-expressing strains. (a) Haemolysis on sheep blood agar by Sterne strain and Sterne expressing PlcR–PapR. (b) Microscopic analysis of spores formed by Sterne and the isogenic PlcR–PapR-expressing strain. (c) Efficacy of sporulation. Shown are mean \pm SD from one representative experiment out of three. (d) Western blot analysis of AtxA activity by determining PA and LF expression in response to bicarbonate/CO₂. Control (CTR) bands represent 1 μ g recombinant protein.

Quantification of sporulation efficacy verified that both strains sporulated with similar high efficacies (Fig. 1c).

Growth of *B. anthracis* at elevated temperatures (above 43 °C) can induce loss of the virulence plasmid pXO1 (Mikesell *et al.*, 1983). To exclude the possibility that pXO1 was lost during growth, we verified the presence of pXO1 by PCR using oligonucleotides specific for the PA gene (*pagA*) (data not shown).

To determine whether a point mutation in the *atxA* gene could have caused inactivation of the regulator, we sequenced the entire *atxA* gene in Sterne 34F2 and Sterne pFP12. The sequences were 100 % identical to the annotated Sterne *atxA* sequence (data not shown), including 470 bp of the upstream promoter region, thereby excluding the possibility that AtxA expression in the PlcR–PapR-positive strain was silenced by mutation.

To rule out the possibility that other unrecognized changes may have inactivated AtxA regulation, we investigated the functionality of AtxA in both the wild-type and pFP12-containing strains. It has been established that expression of *B. anthracis* toxin genes is enhanced by elevated bicarbonate/CO₂ (Leppla, 1988). This higher expression requires AtxA, even though transcription of the regulator itself is not affected by bicarbonate/CO₂ levels (Dai & Koehler, 1997). Analysis of PA and LF expression in Sterne and Sterne pFP12 grown in the presence of bicarbonate/CO₂ showed that both toxins are expressed at similar levels in both strains, verifying that AtxA is functional in both strains (Fig. 1d). These results show that strain Sterne 34F2 is able to sporulate when PlcR–PapR and AtxA are simultaneously active, and that there is no incompatibility of these two regulators, at least in the strains we investigated here.

Activation of the PlcR regulon in *B. anthracis* leads to expression of proteins found in the secretome of *B. cereus*

While the secretomes of *B. cereus* and *B. thuringiensis* are highly similar, *B. anthracis* shows a distinctively different secretome, probably due to the presence of an inactive PlcR (Chitlaru *et al.*, 2006; Gohar *et al.*, 2002). Thus, we assessed the influence of heterologous PlcR–PapR activation in *B. anthracis* on the composition of the bacterial secretome by 2D SDS-PAGE. Fig. 2 shows that the PlcR-expressing *B. anthracis* derivative has a secreted protein profile distinctively different from that of wild-type *B. anthracis*. We selected proteins that appeared unique for MS analysis (Fig. 2, Table 2). We found S-layer proteins SAP/EA1 to be highly abundant in *B. anthracis* lacking PlcR–PapR, indicating either lower expression or degradation by PlcR-regulated proteases. We identified several proteins found in supernatants of *B. cereus*, including homologues of an enterotoxin component (BA1887), phospholipases (BA3891 and BA0677), InhA metalloprotease (BA0672) and a putative protease (BA1995). A protein of unknown function




Fig. 2. 2D SDS-PAGE separation of proteins secreted by Sterne and Sterne pFP12 grown in BHI broth to late exponential phase. Boxed spots indicate proteins identified by MS. Proteins are numbered according to *B. anthracis* Ames (BA) gene ID. See Table 2 for gene descriptions. Molecular mass (in kDa) is given on the left and the pH range is indicated at the top.

(BA2032) showed high expression in PlcR-activated *B. anthracis*, and interestingly the gene is present in all *B. anthracis* strains sequenced to date, but in only four of the sequenced *B. cereus* strains (W-8, AH820, E33L and 95/8201). Analysis of the upstream regions of all identified proteins for a putative PlcR binding site showed that five of them indeed harboured a PlcR box (Table 2). These results demonstrate the effect that activation of the PlcR regulon has on the expression profile of *B. anthracis*, and show that expression of a PlcR–PapR fusion protein causes the secretome of *B. anthracis* to acquire similarities to that of *B. cereus*.


Expression of the putative protease BA1995 is enhanced by PlcR–PapR

One difference between the two *B. anthracis* secretomes examined in Fig. 2 was a protein band of 40–50 kDa that was highly abundant only in the PlcR–PapR-positive strain (Fig. 2). MS identified this as the putative protease BA1995, and matched peptides from the analysis are shown in Fig. 3(a). This protein belongs to the transglutaminase-like superfamily (PFAM 01841) and a homologue is present in *B. cereus* (BC1991). PlcR box homology searches had failed to identify BA1995 and BC1991 as likely to be regulated by PlcR, but our data suggested that BA1995 production might be either directly or indirectly regulated by PlcR. Quantification of the BA1995 gene transcript in these two strains relative to the housekeeping gene *gyrA* showed the amount of transcript for BA1995 to be about eightfold higher in the pFP12-containing strain than in the wild-type, indicating that PlcR can regulate this gene (Fig. 3b). Interestingly, even though the wild-type strain does not have a functional PlcR, low levels of BA1995 mRNA were observed, indicating weak transcription independent of PlcR.

Examination of the region upstream of the BA1995 gene identified a near-perfect PlcR box 82 bases upstream of the start codon (Fig. 3c). The sequence differed from the consensus sequence by a residue that is generally conserved. The region upstream of the *B. cereus* BC1991 gene showed the same deviation from the consensus, which might explain why previous sequence searches failed to identify this gene as being PlcR-dependent.


In *B. anthracis*, transcription of the cytolytic sphingomyelinase and anthrolysin is induced by PlcR–PapR

The genome of *B. anthracis* encodes fewer active haemolysins than that of *B. cereus*. The genes for sphingomyelinase (*sph*) and anthrolysin (*alo*) are intact, whereas the homologues of *B. cereus* haemolysins II (*hlyII*) and III (*hlyIII*) are truncated (Klichko *et al.*, 2003). Phospholipase C (PC-PLC; BA0677), which we were able to detect in culture supernatants of *B. anthracis* having an activated PlcR regulon (Fig. 2), is non-haemolytic on its own (Beecher & Wong, 2000). In *B. cereus*, the *sph* and *clo* genes are regulated by PlcR (Gohar *et al.*, 2008; Lereclus *et al.*, 1996; Pomerantsev *et al.*, 2004; Slamti *et al.*, 2004), and we confirmed that expression of PlcR–PapR in *B. anthracis* results in a haemolytic phenotype. To determine the contribution of each haemolysin, we measured mRNA levels at different time points during growth. In the absence of PlcR, only weak expression of sphingomyelinase and anthrolysin was observed (Fig. 4a). However, constitutive expression of the PlcR–PapR fusion protein greatly enhanced transcription of both haemolysins in the wild-type Sterne strain (Fig. 4a). These results show that both haemolysins are transcribed in the



Although *B. anthracis* is considered non-haemolytic (Burdon, 1956), it has been reported that growth in rich

medium causes anthrolysin production that leads to haemolysis (Shannon *et al.*, 2003). To further evaluate the contribution of anthrolysin to haemolysis, we generated an anthrolysin gene knockout mutant of the Sterne strain and investigated the haemolytic behaviour towards human erythrocytes before and after introduction of pFP12. Supernatants of the pFP12-containing strain were highly haemolytic throughout the growth cycle (Fig. 4b). Supernatants of the PlcR–PapR-negative wild-type strain



showed a much lower degree of haemolysis that was observed only after the onset of stationary phase. In contrast, the anthrolysin knockout strain did not show haemolysis at any point in the growth cycle, and expression of PlcR–PapR in the anthrolysin knockout led to only a very low level of haemolysis ($1.9\% \pm 0.05$). Complementation of the knockout by expressing *alo* on a plasmid under the control of the PA promoter restored haemolysis to the level seen for the Sterne pFP12 transformant (data not shown).

Anthrolysin is a cholesterol binding haemolysin, and addition of cholesterol inhibits its activity (Tweten, 2005). Cholesterol strongly blocked haemolysis by both wild-type Sterne and the pFP12-containing strain (Fig. 4c). No haemolysis was observed for the anthrolysin knockout, and expression of PlcR–PapR in this mutant could not restore the high haemolytic phenotype observed for Sterne pFP12 in the absence of cholesterol. The small residual haemolytic activities of about 3 % seen for both the PlcR–PapR-positive anthrolysin knockout and the PlcR–PapR-positive anthrolysin-containing strain show that other PlcR-dependent haemolysins contribute only slightly. In summary, these results demonstrate that anthrolysin is the main contributor to haemolysis of human erythrocytes by PlcR–PapR-positive and -negative *B. anthracis* and that other PlcR-regulated haemolysins, such as sphingomyelinase, have a negligible effect.

Supernatants of PlcR–PapR-positive *B. anthracis* kill BMDMs in an anthrolysin-independent manner

In vitro, recombinant anthrolysin lyses a variety of cells, including human leukocytes, monocytes and lymphocytes (Mosser & Rest, 2006). We investigated whether anthrolysin contributes to macrophage toxicity, and for comparison included culture supernatants derived from a *B. cereus* strain. To exclude the known cytotoxic effects caused by lethal toxin (LT) on certain macrophages, BMDMs from LT-resistant DBA mice (McAllister *et al.*, 2003) were used. Macrophages treated with *B. cereus* culture supernatants were efficiently lysed, as seen by the lack of purple formazan when compared with cells treated with medium alone (Fig. 5a), and surprisingly, culture supernatants derived from the PlcR–PapR-negative Sterne and anthrolysin-deficient strains were non-toxic (Fig. 5a, b). Treatment of BMDMs with culture supernatants from pFP12-containing bacteria, however, resulted in death of about 50 % of macrophages (Fig. 5b). Heat treatment of supernatants prior to incubation with BMDMs abolished the cytotoxic effect (Fig. 5b). These data show that PlcR-dependent proteins other than LT and anthrolysin are responsible for the observed killing.

Intraperitoneal toxicity of PlcR–PapR-positive *B. anthracis* is not dependent on anthrolysin

Since the PlcR–PapR-positive *B. anthracis* supernatants efficiently killed murine macrophages in an *in vitro* setting,

we hypothesized that similar cytotoxicity might occur *in vivo*. Mice having LT-resistant macrophages were injected intraperitoneally with cell-free culture supernatants derived from various strains. After 45 min, peritoneal contents were collected by lavage. Interestingly, in mice that received injections of supernatants from PlcR–PapR-positive bacteria, we observed intraperitoneal bleeding, as indicated by the presence of erythrocytes (Fig. 6a). This haemorrhaging was highly reproducible and was never detected following injection of supernatants derived from PlcR–PapR-negative bacteria. We also observed this bleeding when *B. cereus*-derived supernatants were injected (results not shown).

The specific cell populations present in the peritoneal washes were assessed by flow cytometry. Two cell populations were missing in the peritoneal washes derived from mice that received injections of supernatants from PlcR–PapR-positive, but not from PlcR–PapR-negative, strains (Fig. 6b). Closer characterization of cell populations using an antibody that binds to the macrophage-specific F4/80 receptor identified the two missing populations as macrophages (Fig. 6c). Quantification of F4/80-positive cells showed a significant ($P < 0.0001$, one-way ANOVA and $P < 0.05$ Tukey test) fivefold reduction in the numbers of macrophages retrieved from mice that received pFP12-containing *B. anthracis* culture supernatants (Fig. 6d). In concurrence with *in vitro* results, this reduction does not appear to depend on anthrolysin, since macrophages were also depleted when the anthrolysin gene was absent (Fig. 6b–d). The toxicity appears to depend on one or more proteins, since heat treatment of supernatants prior to injection completely abolished cytotoxicity (results not shown).

DISCUSSION

Besides the presence of the two large virulence plasmids, truncation of the major regulator PlcR is one of the major differences setting *B. anthracis* apart from other members of the *B. cereus* group (Kolstø *et al.*, 2009). The nonsense mutation leading to truncation of the PlcR protein is identical in all *B. anthracis* isolates so far investigated, thereby strongly suggesting that it is a distinctive and defining trait of this species (Slamti *et al.*, 2004). Inactivation of PlcR has a major effect on protein expression (Gohar *et al.*, 2002) in *B. cereus*; however, little is known about the PlcR regulon in *B. anthracis*, including the identity of genes that retain the potential to be activated by PlcR. To elucidate the role of PlcR in *B. anthracis*, we expressed an active PlcR–PapR hybrid protein from a plasmid (Pomerantsev *et al.*, 2004), thereby activating the latent PlcR regulon. An earlier study suggested that expression of PlcR in *B. anthracis* leads to interference with the pXO1-dependent AtxA regulon, as indicated by the inability of bacteria harbouring both regulators to sporulate (Mignot *et al.*, 2001). Surprisingly, the *B. anthracis* strain containing both regulators that we describe here readily formed spores. This finding deserves further study in




Fig. 5. *In vitro* toxicity towards macrophages of proteins secreted by *Bacillus*. (a) MTT stain of BMDMs treated for 4 h with cell-free bacterial culture supernatants derived from late exponential phase *B. cereus* BC569 (a2), *B. anthracis* (a3), *B. anthracis* pFP12 (a4), *B. anthracis* anthrolysin knockout (a5), *B. anthracis* anthrolysin knockout harbouring pFP12 (a6), and broth-treated control (N.T.) (a1). (b) Quantification of surviving macrophages treated with bacterial culture supernatants before (N.T.; grey bars) and after (H.I.; black bars) heat treatment at 95 °C for 10 min. Shown are mean \pm SD from one representative experiment out of three.

strains having the PlcR–PapR regulon activated in a manner different from that of the fusion protein encoded by pFP12.

We also compared the secretomes of PlcR–PapR-expressing strains with those of their PlcR–PapR-negative counterparts. The secretomes of *B. anthracis* having active or inactive PlcR were distinctively different, and in the former we identified five proteins harbouring a PlcR binding site in their promoter region. It is likely that analysis of all protein spots present in the secretome of PlcR-active *B. anthracis* would have identified even more such proteins. Furthermore, we detected many proteins in the secretome of PlcR-expressing *B. anthracis* that are found in culture supernatants of PlcR-active *B. cereus* (Gohar *et al.*, 2002, 2005). For example, the *B. cereus* homologue of the putative protease BA1995 was present in supernatants of PlcR-expressing *B. anthracis*, but absent in supernatants derived from the PlcR-negative parent strain. The database annotations available for BA1995 note similarities to a transglutaminase-like protease (Makarova *et al.*, 1999), although the function of the protein is unknown. Our hypothesis that this protein is dependent on PlcR was confirmed by semiquantitative RT-PCR. Closer analysis of the BA1995 promoter region revealed a PlcR box having one mismatch at position 11, resulting in the exchange of a highly conserved nucleotide. The protease InhA2 of *B. thuringiensis* also shows an aberrant PlcR consensus sequence (Fedhila *et al.*, 2003), and the effect of base exchanges within the PlcR box on regulator-dependent activity has been investigated. It was found that

mutations within the PlcR consensus lead to lower transcription depending on their location (Gohar *et al.*, 2008). However, the substitution that we identified in the BA1995 PlcR box was not included in the earlier study. Our results showing that BA1995 is still transcribed at a low level in the absence of PlcR imply that changes in the more conserved residues lower the specificity of PlcR for its target sequence, as shown by Gohar *et al.* (2008). Additionally, the ability of PlcR to recognize an aberrant recognition sequence suggests that the PlcR regulon is larger than anticipated.

One striking phenotype of bacteria harbouring a functional PlcR is their haemolytic behaviour on blood agar plates. PlcR–PapR-expressing bacteria were clearly haemolytic, and anthrolysin, the best-characterized haemolysin of *B. anthracis* (Mosser & Rest, 2006; Shannon *et al.*, 2003), was found to be the main contributor, causing lysis of human erythrocytes in PlcR-positive and -negative bacteria. Although sphingomyelinase is transcribed at a low level, its contribution to haemolysis of human erythrocytes appears to be negligible. However, the content of sphingomyelin in the membrane of human red blood cells is low when compared with other species. In sheep, sphingomyelin can make up to 50 % of the phospholipids present in the red blood cell membrane (Ikezawa *et al.*, 1980); therefore, for detection of sphingomyelinase activity, erythrocytes of other species are expected to be a better indicator.

Macrophages are key players during anthrax pathogenesis, functioning as vehicles for transport of phagocytosed




Fig. 6. *In vivo* macrophage toxicity of proteins secreted by *Bacillus*. (a) Intraperitoneal (IP) washes of mice ($n=2$) treated with 500 μ l filter-sterilized bacterial culture supernatants derived from *B. anthracis* or *B. anthracis* anthrolysin knockout strain in the presence or absence of PlcR–PapR. Control animals were treated with BHI broth alone. (b) Flow cytometry analysis showing forward and side scatter of IP washes derived from mice treated with cell-free bacterial culture supernatants. Arrows indicate macrophage (F4/80+) populations lacking in washes treated with supernatants derived from PlcR–PapR-expressing bacteria. (c) Chart of macrophage (F4/80+) populations present in IP washes of mice treated with bacterial supernatants or with BHI alone. (d) Quantification of macrophages (%) present in the IP washes of mice treated with bacterial culture supernatants. Percentages represent the number of F4/80+ cells relative to the entire cell population present in the IP wash. Shown are mean \pm SD from one representative experiment out of three.

spores to peripheral lymph nodes. Mosser & Rest (2006) have shown that recombinant anthrolysin and supernatants derived from *B. anthracis* are able to kill a variety of cells, including macrophages derived from peripheral human blood. Surprisingly, we found no toxic response in macrophages treated with supernatants from *B. anthracis* Sterne. However, the final concentration of 25 % supernatant in our cell assay may be lower than the concentrations used by Mosser & Rest (2006). In contrast, macrophages treated *in vitro* and *in vivo* with culture supernatants derived from PlcR–PapR-expressing bacteria were killed, and deletion of anthrolysin expression did not have an effect, indicating that toxin(s) other than anthrolysin were responsible for the killing. For *B. cereus*, the PlcR-dependent expression of multiple toxins has been described, including the non-haemolytic enterotoxin (Nhe), which is a three-component toxin associated with food poisoning (Lund & Granum, 1996). *B. anthracis* is known to express NheA in a

PlcR-independent manner (Mendelson *et al.*, 2004), yet it is likely that activation of PlcR increases expression, since its promoter harbours a PlcR box. Concomitantly, we found NheA (BA1887) in the supernatant of *B. anthracis* expressing PlcR. Many other toxins and virulence factors, including proteases and phospholipases, are dependent on PlcR (Gohar *et al.*, 2002), and all of them could contribute to toxicity towards macrophages. The specificity with which the macrophage population was targeted in our *in vivo* studies was surprising, indicating a crucial role for these cells. PlcR is truncated in all known *B. anthracis* strains to date, and silencing of these unknown toxin(s) that mediate macrophage killing could be the reason why mutation of PlcR was favoured in these strains. The exact mechanism by which PlcR-reconstituted *B. anthracis* attacks macrophages and the identity of the toxin(s) involved deserve further investigation, especially in strains harbouring both virulence plasmids.

ACKNOWLEDGEMENTS

This work was supported by the Intramural Research Program of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA. We thank Zachary Newman for supplying BMDM cells, Deborah Crown for assistance with animal experiments, the NIAID RTB for performing 2D SDS-PAGE and MS, and Dr Clinton Leysath for assistance with flow cytometry. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the US Government.

REFERENCES

- Agaisse, H., Gominet, M., Okstad, O. A., Kolstø, A. B. & Lereclus, D. (1999). PlcR is a pleiotropic regulator of extracellular virulence factor gene expression in *Bacillus thuringiensis*. *Mol Microbiol* **32**, 1043–1053.
- Beecher, D. J. & Wong, A. C. (2000). Cooperative, synergistic and antagonistic haemolytic interactions between haemolysin BL, phosphatidylcholine phospholipase C and sphingomyelinase from *Bacillus cereus*. *Microbiology* **146**, 3033–3039.
- Bouillaut, L., Perchat, S., Arold, S., Zorrilla, S., Slamti, L., Henry, C., Gohar, M., Declerck, N. & Lereclus, D. (2008). Molecular basis for group-specific activation of the virulence regulator PlcR by PapR heptapeptides. *Nucleic Acids Res* **36**, 3791–3801.
- Burdon, K. L. (1956). Useful criteria for the identification of *Bacillus anthracis* and related species. *J Bacteriol* **71**, 25–42.
- Chitlaru, T., Gat, O., Gozlan, Y., Ariel, N. & Shafferman, A. (2006). Differential proteomic analysis of the *Bacillus anthracis* secretome: distinct plasmid and chromosome CO₂-dependent cross talk mechanisms modulate extracellular proteolytic activities. *J Bacteriol* **188**, 3551–3571.
- Dai, Z. & Koehler, T. M. (1997). Regulation of anthrax toxin activator gene (*atxA*) expression in *Bacillus anthracis*: temperature, not CO₂/bicarbonate, affects AtxA synthesis. *Infect Immun* **65**, 2576–2582.
- Drobniewski, F. A. (1993). *Bacillus cereus* and related species. *Clin Microbiol Rev* **6**, 324–338.
- Emanuelsson, O., Brunak, S., von Heijne, G. & Nielsen, H. (2007). Locating proteins in the cell using TargetP, SignalP and related tools. *Nat Protoc* **2**, 953–971.
- Fedhila, S., Gohar, M., Slamti, L., Nel, P. & Lereclus, D. (2003). The *Bacillus thuringiensis* PlcR-regulated gene *inhA2* is necessary, but not sufficient, for virulence. *J Bacteriol* **185**, 2820–2825.
- Gardy, J. L., Laird, M. R., Chen, F., Rey, S., Walsh, C. J., Ester, M. & Brinkman, F. S. (2005). PSORTb v.2.0: expanded prediction of bacterial protein subcellular localization and insights gained from comparative proteome analysis. *Bioinformatics* **21**, 617–623.
- Gohar, M., Okstad, O. A., Gilois, N., Sanchis, V., Kolstø, A. B. & Lereclus, D. (2002). Two-dimensional electrophoresis analysis of the extracellular proteome of *Bacillus cereus* reveals the importance of the PlcR regulon. *Proteomics* **2**, 784–791.
- Gohar, M., Gilois, N., Graveline, R., Garreau, C., Sanchis, V. & Lereclus, D. (2005). A comparative study of *Bacillus cereus*, *Bacillus thuringiensis* and *Bacillus anthracis* extracellular proteomes. *Proteomics* **5**, 3696–3711.
- Gohar, M., Faegri, K., Perchat, S., Ravnum, S., Okstad, O. A., Gominet, M., Kolstø, A. B. & Lereclus, D. (2008). The PlcR virulence regulon of *Bacillus cereus*. *PLoS ONE* **3**, e2793.
- Helgason, E., Okstad, O. A., Caugant, D. A., Johansen, H. A., Fouet, A., Mock, M., Hegna, I. & Kolstø, A. B. (2000). *Bacillus anthracis*, *Bacillus cereus*, and *Bacillus thuringiensis* – one species on the basis of genetic evidence. *Appl Environ Microbiol* **66**, 2627–2630.
- Hoffmaster, A. R., Ravel, J., Rasko, D. A., Chapman, G. D., Chute, M. D., Marston, C. K., De, B. K., Sacchi, C. T., Fitzgerald, C. & other authors (2004). Identification of anthrax toxin genes in a *Bacillus cereus* associated with an illness resembling inhalation anthrax. *Proc Natl Acad Sci U S A* **101**, 8449–8454.
- Hoffmaster, A. R., Hill, K. K., Gee, J. E., Marston, C. K., De, B. K., Popovic, T., Sue, D., Wilkins, P. P., Avashia, S. B. & other authors (2006). Characterization of *Bacillus cereus* isolates associated with fatal pneumonias: strains are closely related to *Bacillus anthracis* and harbor *B. anthracis* virulence genes. *J Clin Microbiol* **44**, 3352–3360.
- Ikezawa, H., Mori, M. & Taguchi, R. (1980). Studies on sphingomyelinase of *Bacillus cereus*: hydrolytic and hemolytic actions on erythrocyte membranes. *Arch Biochem Biophys* **199**, 572–578.
- Ivanova, N., Sorokin, A., Anderson, I., Galleron, N., Candelon, B., Kapatral, V., Bhattacharyya, A., Reznik, G., Mikhailova, N. & other authors (2003). Genome sequence of *Bacillus cereus* and comparative analysis with *Bacillus anthracis*. *Nature* **423**, 87–91.
- Ivins, B. E., Ezzell, J. W., Jr, Jemski, J., Hedlund, K. W., Ristroph, J. D. & Leppla, S. H. (1986). Immunization studies with attenuated strains of *Bacillus anthracis*. *Infect Immun* **52**, 454–458.
- Klee, S. R., Ozel, M., Appel, B., Boesch, C., Ellerbrok, H., Jacob, D., Holland, G., Leendertz, F. H., Pauli, G. & other authors (2006). Characterization of *Bacillus anthracis*-like bacteria isolated from wild great apes from Côte d'Ivoire and Cameroon. *J Bacteriol* **188**, 5333–5344.
- Klichko, V. I., Miller, J., Wu, A., Popov, S. G. & Alibek, K. (2003). Anaerobic induction of *Bacillus anthracis* hemolytic activity. *Biochem Biophys Res Commun* **303**, 855–862.
- Kolstø, A. B., Tourasse, N. J. & Okstad, O. A. (2009). What sets *Bacillus anthracis* apart from other *Bacillus* species? *Annu Rev Microbiol* **63**, 451–476.
- Leppla, S. H. (1988). Production and purification of anthrax toxin. *Methods Enzymol* **165**, 103–116.
- Lereclus, D., Agaisse, H., Gominet, M., Salamitou, S. & Sanchis, V. (1996). Identification of a *Bacillus thuringiensis* gene that positively regulates transcription of the phosphatidylinositol-specific phospholipase C gene at the onset of the stationary phase. *J Bacteriol* **178**, 2749–2756.
- Lund, T. & Granum, P. E. (1996). Characterisation of a non-haemolytic enterotoxin complex from *Bacillus cereus* isolated after a foodborne outbreak. *FEMS Microbiol Lett* **141**, 151–156.
- Makarova, K. S., Aravind, L. & Koonin, E. V. (1999). A superfamily of archaeal, bacterial, and eukaryotic proteins homologous to animal transglutaminases. *Protein Sci* **8**, 1714–1719.
- McAllister, R. D., Singh, Y., Du Bois, W. D., Potter, M., Boehm, T., Meeker, N. D., Fillmore, P. D., Anderson, L. M., Poynter, M. E. & other authors (2003). Susceptibility to anthrax lethal toxin is controlled by three linked quantitative trait loci. *Am J Pathol* **163**, 1735–1741.
- Mendelson, I., Tobery, S., Scorpio, A., Bozue, J., Shafferman, A. & Friedlander, A. M. (2004). The NheA component of the non-hemolytic enterotoxin of *Bacillus cereus* is produced by *Bacillus anthracis* but is not required for virulence. *Microb Pathog* **37**, 149–154.
- Mignot, T., Mock, M., Robichon, D., Landier, A., Lereclus, D. & Fouet, A. (2001). The incompatibility between the PlcR- and AtxA-controlled regulons may have selected a nonsense mutation in *Bacillus anthracis*. *Mol Microbiol* **42**, 1189–1198.

- Mikesell, P., Ivins, B. E., Ristroph, J. D. & Dreier, T. M. (1983). Evidence for plasmid-mediated toxin production in *Bacillus anthracis*. *Infect Immun* **39**, 371–376.
- Mock, M. & Fouet, A. (2001). Anthrax. *Annu Rev Microbiol* **55**, 647–671.
- Mosser, E. M. & Rest, R. F. (2006). The *Bacillus anthracis* cholesterol-dependent cytolysin, anthrolysin O, kills human neutrophils, monocytes and macrophages. *BMC Microbiol* **6**, 56.
- Okstad, O. A., Gominet, M., Purnelle, B., Rose, M., Lereclus, D. & Kolstø, A. B. (1999). Sequence analysis of three *Bacillus cereus* loci carrying PlcR-regulated genes encoding degradative enzymes and enterotoxin. *Microbiology* **145**, 3129–3138.
- Park, S. & Leppla, S. H. (2000). Optimized production and purification of *Bacillus anthracis* lethal factor. *Protein Expr Purif* **18**, 293–302.
- Passalacqua, K. D., Varadarajan, A., Byrd, B. & Bergman, N. H. (2009). Comparative transcriptional profiling of *Bacillus cereus* sensu lato strains during growth in CO₂–bicarbonate and aerobic atmospheres. *PLoS ONE* **4**, e4904.
- Pomerantsev, A. P., Kalnin, K. V., Osorio, M. & Leppla, S. H. (2003). Phosphatidylcholine-specific phospholipase C and sphingomyelinase activities in bacteria of the *Bacillus cereus* group. *Infect Immun* **71**, 6591–6606.
- Pomerantsev, A. P., Pomerantseva, O. M. & Leppla, S. H. (2004). A spontaneous translational fusion of *Bacillus cereus* PlcR and PapR activates transcription of PlcR-dependent genes in *Bacillus anthracis* via binding with a specific palindromic sequence. *Infect Immun* **72**, 5814–5823.
- Pomerantsev, A. P., Camp, A. & Leppla, S. H. (2009). A new minimal replicon of *Bacillus anthracis* plasmid pXO1. *J Bacteriol* **191**, 5134–5146.
- Rasko, D. A., Altherr, M. R., Han, C. S. & Ravel, J. (2005). Genomics of the *Bacillus cereus* group of organisms. *FEMS Microbiol Rev* **29**, 303–329.
- Read, T. D., Peterson, S. N., Tourasse, N., Baillie, L. W., Paulsen, I. T., Nelson, K. E., Tettelin, H., Fouts, D. E., Eisen, J. A. & other authors (2003). The genome sequence of *Bacillus anthracis* Ames and comparison to closely related bacteria. *Nature* **423**, 81–86.
- Reddy, A., Battisti, L. & Thorne, C. B. (1987). Identification of self-transmissible plasmids in four *Bacillus thuringiensis* subspecies. *J Bacteriol* **169**, 5263–5270.
- Ross, C. L. & Koehler, T. M. (2006). *plcR papR*-independent expression of anthrolysin O by *Bacillus anthracis*. *J Bacteriol* **188**, 7823–7829.
- Sastalla, I., Chim, K., Cheung, G. Y., Pomerantsev, A. P. & Leppla, S. H. (2009). Codon-optimized fluorescent proteins designed for expression in low-GC Gram-positive bacteria. *Appl Environ Microbiol* **75**, 2099–2110.
- Shannon, J. G., Ross, C. L., Koehler, T. M. & Rest, R. F. (2003). Characterization of anthrolysin O, the *Bacillus anthracis* cholesterol-dependent cytolysin. *Infect Immun* **71**, 3183–3189.
- Slamti, L., Perchat, S., Gominet, M., Vilas-Boas, G., Fouet, A., Mock, M., Sanchis, V., Chauvaux, J., Gohar, M. & other authors (2004). Distinct mutations in PlcR explain why some strains of the *Bacillus cereus* group are nonhemolytic. *J Bacteriol* **186**, 3531–3538.
- Tweten, R. K. (2005). Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. *Infect Immun* **73**, 6199–6209.

Edited by: S. J. Foster